Human cytomegalovirus neutralizing antibodies and use thereof

Details Human cytomegalovirus neutralizing antibodies and use thereof Human cytomegalovirus neutralizing antibodies and use thereof

2011-06-07

2011-06-07

Lucas, Zachariah (Department: 1648)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S141100, C424S159100, C424S229100, C424S230100, C530S388300, C530S388200, C530S388100, C530S387100

Reexamination Certificate

active

07955599

ABSTRACT:
The invention relates to neutralising antibodies which are specific for human cytomegalovirus and bind with high affinity as well as immortalised B cells that produce such antibodies. The invention also relates to the epitopes that the antibodies bind to as well as the use of the antibodies and the epitopes in screening methods as well as the diagnosis and therapy of disease.

REFERENCES:
patent: 4294817 (1981-10-01), Burgett et al.
patent: 4313927 (1982-02-01), Fridlender
patent: 4334016 (1982-06-01), Furukawa
patent: 4743562 (1988-05-01), Rasmussen et al.
patent: 4783399 (1988-11-01), Oldstone et al.
patent: 4804627 (1989-02-01), Hammerling et al.
patent: 4808518 (1989-02-01), Dorsett et al.
patent: 5043281 (1991-08-01), Masuho et al.
patent: 5126130 (1992-06-01), Lussenhop et al.
patent: 5180813 (1993-01-01), Stinski
patent: 5194654 (1993-03-01), Hostetler et al.
patent: 5750106 (1998-05-01), Ostberg
patent: 6120989 (2000-09-01), Vornhagen et al.
patent: 6828113 (2004-12-01), Witkin
patent: 2006/0216302 (2006-09-01), Root-Bernstein
patent: 2008/0014208 (2008-01-01), Reiter et al.
patent: 2008/0107620 (2008-05-01), Khanna
patent: 2008/0187545 (2008-08-01), Shenk et al.
patent: 2008/0213265 (2008-09-01), Lanzavecchia et al.
patent: 2008/0248042 (2008-10-01), De Re et al.
patent: 2009/0004198 (2009-01-01), Nakajima et al.
patent: 2009/0162378 (2009-06-01), Lai et al.
patent: 122841 (1984-10-01), None
patent: 128522 (1984-12-01), None
patent: 162533 (1985-11-01), None
patent: 165830 (1985-12-01), None
patent: 198086 (1986-10-01), None
patent: 248909 (1987-12-01), None
patent: 277071 (1988-08-01), None
patent: 0314161 (1989-05-01), None
patent: 484765 (1992-05-01), None
patent: 527785 (1993-02-01), None
patent: 534102 (1993-03-01), None
patent: 564735 (1993-10-01), None
patent: 680333 (1995-11-01), None
patent: 683675 (1995-11-01), None
patent: 802979 (1997-10-01), None
patent: 832253 (1998-04-01), None
patent: 835122 (1998-04-01), None
patent: 837928 (1998-04-01), None
patent: 882132 (1998-12-01), None
patent: 926155 (1999-06-01), None
patent: 960336 (1999-12-01), None
patent: 964686 (1999-12-01), None
patent: 973536 (2000-01-01), None
patent: 996730 (2000-05-01), None
patent: 1003841 (2000-05-01), None
patent: 1034289 (2000-09-01), None
patent: 1304574 (2003-04-01), None
patent: 1061943 (2002-10-01), None
patent: 8803952 (1988-06-01), None
patent: 90/01497 (1990-02-01), None
patent: 91/04277 (1991-04-01), None
patent: 91/05876 (1991-05-01), None
patent: 93/21952 (1993-11-01), None
patent: WO 94/09136 (1994-04-01), None
patent: 94/16730 (1994-08-01), None
patent: 9425490 (1994-11-01), None
patent: 0000223 (2000-01-01), None
patent: 0016061 (2000-03-01), None
patent: 03/085121 (2003-10-01), None
patent: 2004/076677 (2004-09-01), None
patent: 2007/068758 (2007-06-01), None
patent: 2007/094423 (2007-08-01), None
patent: 2007/146024 (2007-12-01), None
patent: 2008071806 (2008-06-01), None
patent: 2008/084410 (2008-07-01), None
patent: 2008120203 (2008-10-01), None
patent: 2009024445 (2009-02-01), None
patent: 2009085383 (2009-07-01), None
Vajdos et al., Comprehensive Functional Maps of the Antigenbinding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, 2002, Journal of Molecular Biology, vol. 320, pp. 415-428.
Takekoshi et al., Human monoclonal anti-HCMV neutralizing antibody from phage display libraries, 1998, Journal of Virological Methods, vol. 74, pp. 89-98.
Masuho et al., Human Monoclonal Antibodies Neutralizing Human Cytomegalovirus, 1987, Journal of General Virology, vol. 68, pp. 1457-1461.
Patrone et al., Human Cytomegalovirus UL130 Protein Promotes Endothelial Cell Infection through a Producer Cell Modification of the Virion, 2005, Journal of Virology, vol. 79, No. 13, pp. 8361-8373.
Goldsby et al., (Immunology, 5thEd., 2003, W.H. Freeman and Company, pp. 83-85.
Rudikoff et a., Single amino acid substitution altering antigen-binding specificity, 1982, PNAS, vol. 79, pp. 1979-1983.
Adler, Barbara et al., “Role of human cytomegalovirus UL131A in cell type-specific virus entry and release,” Journal of General Virology, vol. 87:2451-2460 (2006).
Baba, Timothy W. et al., “Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection,” Nature Medicine, vol. 6(2):200-206 (2000).
Drosten, Christian et al., “Identification of a Novel Coronavirus in Patients with Severe Acute Respiratory Syndrome,” The New England Journal of Medicine, vol. 348:1967-1976 (2003).
Foung, Steven K.H. et al., “Human Monoclonal Antibodies to Human Cytomegalovirus,” The Journal of Infectious Diseases, vol. 159 (3):436-443 (1989).
Funaro, Ada et al., “Generation of potent neutralizing human monoclonal antibodies against cytomegalovirus infection from immune B cells,” BMC Biotechnologies, vol. 8:85 doi:10.1186/1472-6750-8-85 (2008).
Gerna, Giuseppe et al., “Human cytomegalovirus serum neutralizing antibodies block virus infection of endothelial/epithelial cells, but not fibroblasts, early during primary infection,” Journal of General Virology, vol. 89:853-865 (2008).
Invitrogen, “Mammalian Cell Culture,” retrieved online at: http://www.invitrogen.com/site/us/en/home/Products-and-Services/Applications/Cell-Culture.html (2010).
Lanzavecchia, Antonio, “Monoclonal antibody production by EBV transformation of B cells,” not yet published U.S. Appl. No. 11/719,835, filed Feb. 26, 2004; Institute for Research in Biomedicine.
Macagno, Annalisa et al., “Isolation of Human Monoclonal Antibodies That Potently Neutralize Human Cytomegalovirus Infection by Targeting Different Epitopes on the gH/gL/UL128-131A Complex,” Journal of Virology, vol. 84(2):1008-1013 (2010).
Mach, M. et al., “Complex Formation by Human Cytomegalovirus Glycoproteins M (gpUL100) and N (gIUL73),” Journal of Virology, vol. 74(24):11881-11892 (2000).
Mazeron, M.C. et al., “Monoclonal antibody E-13 (M-810) to human cytomegalovirus recognizes an epitope encoded by exon 2 of the major immediate early gene,” Journal of General Virology, vol. 73:2699-2703 (1992).
Mulder, A. et al., “A human monoclonal antibody, produced following in vitro immunization, recognizing an epitope shared by HLA-A2 subtypes and HLA-A28,” Tissue Antigens, vol. 42:27-34 (1993).
National BioResource Project (NBRP)::E.coliStrain, “About Cloning Vector Collection,” retreived online at: http://www.shigen.nig.ac.jp/ecoli/strain/cvector/cvectorExplanation.jsp (2009).
Niedbala, Wanda G. et al., “A Comparison of Three Methods for Production of Human Hybridomas Secreting Autoantibodies,” Hybridoma, vol. 17(3):299-304 (1998).
Ohlin, Mats et al., “Cytomegalovirus Glycoprotein B-Specific Antibody Analysis Using Electrochemiluminescence Detection-Based Techniques,” Clinical and Diagnostic Laboratory Immunology, vol. 4(1):107-111 (1997).
Ryckman, Brent J. et al., “Characterization of the Human Cytomegalovirus gH/gL/UL128-131 Complex That Mediates Entry into Epithelial and Endothelial Cells,” Journal of Virology, vol. 82(1):60-70 (2008).
Wang, Dai et al., “Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism,” PNAS, vol. 102(50):18153-18158 (2005).
European Office Action for Application No. 08737590, dated Feb. 17, 2010.
International Preliminary Report on Patentability for Application No. PCT/IB2008/001111, dated Jul. 7, 2009.
International Search Report for Application No. PCT/IB2008/001111, dated Nov. 3, 2008.
Written Opinion for Application No. PCT/IB2008/002683, dated. Jul. 7, 2009.
International Search Report for Application No. PCT/IB2008/002683, dated Mar. 30, 2009.
Invitation to Pay Additional Fees with Partial International Search for Application No. PCT/IB2008/006641, dated Mar. 11, 2010.
Mclean, G. et al., “Recognition of human cytomegalovirus by human primary immunoglobulins identifies an innate foundation

Affiliated with

Also associated with

Rating

Human cytomegalovirus neutralizing antibodies and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human cytomegalovirus neutralizing antibodies and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cytomegalovirus neutralizing antibodies and use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2730867